Analysis
Technology
Spectral Flow Cytometry Panel Design: Why 60 Markers Use Two Panels
Two complementary five-laser Aurora panels cover 60 unique PBMC markers and more than 50 phenotypic populations, but they cannot measure all 60 markers on the same cell.
Technical Review · DOI: 10.3389/fimmu.2026.1894779. Source peer-reviewed original research method for immunomonitoring (not diagnostic validation); CFCM editorial synthesis, not independent clinical validation.
More markers do not always belong in one tube
The relevant design target is separability of the populations and states that answer a biological question, not the largest possible single-panel marker count. A complementary panel strategy may preserve resolution where a single highly complex panel would sacrifice assay robustness.
What the 2026 methods study established
Rietdijk and colleagues developed two spectral panels with 60 unique markers to characterise more than 50 phenotypic PBMC populations. Their optimisation on a five-laser Cytek Aurora combined deliberate marker allocation, staining-order controls, unmixing and manual gating with unsupervised exploratory analyses. The work included eight healthy donors and nineteen patient samples from glioblastoma, chronic inflammation and COVID-19 cohorts.
Sampling limits determine the rare populations you can defend
The authors set a minimum of one million viable PBMCs for both panels, corresponding to 500,000 per panel for rare-event analysis. That is a sampling requirement in this method, not a universal limit of detection. Rare population frequency, acquisition completeness and gate definitions remain necessary to interpret any percentage.
Why portability and clinical claims require more work
The demonstrated performance concerns PBMCs on the instrument and configuration evaluated. The authors did not validate transfer to other manufacturers or clinical diagnosis, and changes in specimen type would require re-optimisation. Treat marker allocation, antibody titre, unmixing references, acquisition and manual/unsupervised agreement as a new verification programme when adopting this approach.

Daily Learning Pill
Two complementary panels can improve biological coverage, but they do not create a single-cell 60-marker measurement. Never compare cross-panel coexpression as though it came from one event.
Explore the related CFCM resources and troubleshooting guides. Full primary source: read the paper.